wint20200514_corresp.htm

 

Windtree Therapeutics, Inc.

2600 Kelly Road, Suite 100

Warrington, PA 18976

 

May 15, 2020

 

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Manufacturing

100 F Street NE

Washington, D.C. 20549

Attn: Jeffery Gabor

 

Re: 

Windtree Therapeutics, Inc.

Registration Statement on Form S-1
SEC File No. 333-236085

Filed January 27, 2020

   

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Windtree Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-236085) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 5:00 PM, eastern time, on May 18, 2020, or as soon thereafter as is practicable.

 

Please feel free to direct any questions or comments concerning this request to Rachael Bushey, Esq. of Pepper Hamilton LLP at (215) 981-4331.

 

The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

 

 

WINDTREE THERAPEUTICS, INC.

 

 

 

 

 

 

 

By:

/s/ Craig E. Fraser

 

 

Name: Craig E. Fraser

 

 

Title: President, Chief Executive Officer

 

 

Cc: Rachael Bushey, Pepper Hamilton LLP

 

 

 

Windtree Therapeutics, Inc. – Acceleration Letter